In patients with tough-to-treat forms of epilepsy, Zogenix's (NASDAQ:ZGNX) ZX008 may work better than GW Pharmaceuticals' (NASDAQ:GWPH) marijuana-based drug, Epidiolex. Can ZX008 give Epidiolex a run for its money, or will perceptions about its safety derail demand?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,